PTPN11 and systemic mastocytosis: Together with our results implicating SHP2 in promoting aggressive SM disease in mice, and the effects of SHP2 inhibitor treatment in vitro, we conclude that SHP2 inhibitors could be effective in combination with kinase inhibitors such as Dasatinib for treating aggressive SM.